• Mass cytometry reveals a Treg immune signature for aplastic anemia (AA), and for response to ATG.
Introduction
Treatment options for idiopathic aplastic anemia(AA) include allogeneic hematopoietic stem cell transplantation (HSCT) or immunosuppressive therapy (IST), and recently eltrombopag for refractory severe AA. [1] [2] [3] Some patients are ineligible for HSCT due to older age or lack of a suitable donor, and following IST a third of patients fail to respond and 35% relapse after responding. Up to 20% of patients transform to myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) after IST [3] [4] [5] [6] [7] . Additional novel therapeutic approaches are needed for AA patients who fail to respond to IST, and alongside this, more robust diagnostic tests that predict response to IST.
We, and others, have shown a reduction in the number and function of Tregs in AA [8] [9] [10] [11] .
Tregs from AA patients also secrete pro-inflammatory cytokines 8 . Correlation between number and function of Tregs and response to standard IST has not been fully investigated, and it is unclear whether the dominant Treg subpopulation in AA is more of a T conventional(Tcon) subtype or are genuinely functional Tregs.
The aims of this study were (i) to identify an immune signature for AA compared to healthy individuals, based on Treg subpopulations and Tcon (ii) to identify the immune signature that predicts response to IST at time of diagnosis of AA and (iii) to examine the expandability and characteristics of Treg subpopulations that may form the basis for novel therapeutic approach to AA patients who are refractory to IST. For this, we utilized a novel deep-phenotyping strategy using multi-parameter mass cytometry (known as cytometry by time-of-flight (CyTOF)) and automated clustering method including t-distributed stochastic neighbour embedding (t-SNE) 12 to visually (viSNE) identify cell populations 13 in combination with spanning-tree progression analysis of density-normalized events (SPADE) 14 . This enabled us to identify two distinct subpopulations of human Tregs in AA and healthy age matched donors (HDs), and to demonstrate clear differences in AA that predicted response to IST. We also showed that AA Tregs can be expanded in-vitro and that they are stable and functional.
Methods

Patients and healthy donors
Thirty-nine AA patients at diagnosis and 31 HDs were recruited(summarized in table-1).
Peripheral blood mononuclear cells(PBMCs) from 16 patients (12 IST-responder and 4 nonresponders) were used for initial CyTOF analysis and samples from another 15 patients(11 ISTresponders and 4 non-responders) were used as validation cohort. PBMCs from additional 8 patients were used for functional assays in addition to 4 patients from the initial cohort. Response to IST was evaluated at 6 months post-therapy. Median age was 45 years (range 20-72 years). IST eligible AA patients were randomly invited to participate in this study. All patients< 35 years old were screened for Fanconi anemia.
Antibodies and cell staining
We designed a panel of antibodies based on surface markers, transcription factors and cytokines (table-s1 ). Each antibody was tagged with a rare metal isotope and its function verified by conventional flow-cytometry prior to mass-cytometry (supplementary methods). CyTOF-2 mass cytometer(Fluidigm) was used for data acquisition. Acquired data were normalized based on normalization beads (Ce 140, Eu151, Eu153, Ho165 and Lu175). 15 
Data processing, scale transformation, automated clustering and distance computations
Data were initially processed and analyzed using Cytobank. 16 The stand-alone analysis tool cyt was also used for performing t-SNE dimensionality reduction and merging distinct FCS files 13 .
We analyzed mass-cytometry complex data using viSNE 12 to visually identify delineate subpopulations 13 in combination with SPADE 14 and heatmaps 15 . To distinguish CD4 + T-cell subpopulations, in particular Tregs. 15 See the supplementary material and methods.
Treg expansion
Freshly isolated live Tregs were stimulated with anti CD3/CD28 beads(1:1 ratio) (Dynabeads human T-activator CD3/CD28, Life Technologies) and high dose(1,000 IU/ml) interleukin-2 (IL-2)(Proleukin, Novartis) for four weeks with all-trans retinoic acid(ATRA) 2 μM (Sigma Aldrich) and rapamycin(Rapa) 100 nM(Alfa-Aesar). Culture medium (XV Prime, Irvine
Scientific supplemented with AB serum 10%) and beads was replenished every week. After 4 weeks of expansion, cells were rested with decreasing doses of IL-2 for 5 days. 18, 19, 20 .
T-cell receptor diversity
Gene expression
RNA extraction method is included in supplementary methods. Analysis of differential gene expression was performed as previously described 21, 22 (supplementary methods).
GEP data of this manuscript is deposited at gene expression omnibus(GEO), accession number: GSE78004
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=qvclwscgnxgvtkz&acc=GSE78004
Statistical analysis
Different statistical methods have been used which are explained in the result section and/or figure legends. P < 0.05 was considered as statistically significant in all cases. Statistics were calculated using SPSS version 22 or R version 3.2.2.
Study approval
King's College Hospital Local Research Ethics Committee and Institutional Review Board of the National Heart, Lung, and Blood Institute (NIH) approved the clinical studies of IST and sample collection, and informed written consent was obtained from patients. between AA and HDs were identified and designated as "Treg A" and "Treg B" (figure-2c&d and figure-S1b&c). To confirm the presence of these two subpopulations and eliminate any bias, dimensionality reduction and automated unsupervised clustering methodology was applied independently by the bioinformatician that confirmed the presence of two subpopulations within Tregs (figure-2c and figure-S1b&c). These two subpopulations showed distinct markers in AA 
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p=0.01)(figure-S4).
Conventional CD4 + T-cells
Our marker panels also identified and clustered conventional CD4 + T-cells (Tcon Genomic DNA from sorted Tregs A and B was used for T-cell receptor (TCR) Vß chain complementarity determining regions (CDR3) high-throughput sequencing 19, 20 . On average, subpopulation A and B had 33773 and 26090 unique TCR sequences, respectively, and 233 sequences were common to both (r=0.008) (figure-S6). Tcon also shared 137 and 383 sequences with subpopulation A and B respectively (r=0.154 and r=0.092 respectively). It is recognized that in assessment of naturally, highly diverse TCR subpopulations, under-sampling can introduce bias 18 24 . We therefore used Power Geometric index (PG) for pairwise comparison of TCR repertoire overlap 18 . Overlap between Treg A, B and Tcon was small suggesting these subpopulations were distinct (figure-4b).
Global gene expression (GEP) analysis of Treg subpopulations
Whole GEP data 25, 26 showed both Treg A and Treg B had different GEP compared to Tcon.
Nevertheless, when principle component analysis (PCA) was performed, Treg B and Tcon had the highest difference while Treg A subpopulation showed a transcriptional profile in between Treg B
and Tcon (figure-S7).
Comparing GEPs of Treg subpopulations to Tcon, using the human Treg's gene-signature, 27 , showed both Treg A and B subpopulations were significantly enriched in genes up-regulated in 28, 29 .
Expandability of Tregs in Treg promoting culture
One of the aims of this study was to investigate the potential expandability of Tregs in AA.
We first tested the IL-2 sensitivity of AA total Tregs based on STAT5 phosphorylation. 30 Freshly To test their in-vitro expandability, Tregs were obtained from 6 AA patients (3 ISTresponders and 3 non-responders, at diagnosis) and 8 HDs and were cultured and stimulated with anti CD3/CD28 beads (1:1 ratio) and high dose IL-2 (1,000 IU/mL) for four weeks with added alltrans retinoic acid 2 µM and rapamycin 100 nM. 17 /l, respectively 39 . Short telomeres in children, but not in adults, also predict response to IST 40, 41 . The presence of a PIGA mutation predicts for response to IST, as does a somatic BCOR/BCORL mutation. In contrast, somatic mutation of DNMT3A or ASXL1 is associated with worse outcomes following IST 42 . We have identified an immune signature that predicts for response to IST for an individual patient at time of diagnosis of AA. Non-responders to IST were more likely to have higher Treg A compared to non-responders, whereas responders had higher Treg B numbers compared to HDs(figure-7). Treg B subpopulation characterized by a more "activated/memory" phenotype. We also tested this combination of identified markers in a separate validation cohort of AA patients, using conventional flow-cytometry, and confirmed the predictive value of this combination for response to IST.
To explore the potential therapeutic application of expanded Tregs in the treatment of AA, we examined the characteristics and in vitro expandability of the Treg subpopulations in depth.
Both In-vitro expansion of Tregs for clinical use is an emerging cellular therapy in GVHD, type-I diabetes and organ transplant rejection. [48] [49] [50] [51] [52] Nevertheless, the quality control of expanded Tregs is a time consuming procedure. Our data comparing expanded Tregs with pre-expansion Treg subpopulations could provide a robust and quick screening for quality control of cell therapy products, and may serve as a predictive tool for expandability of Tregs in AA and other autoimmune diseases.
In summary, we have shown for the first time that a novel strategy for multidimensional deep-phenotyping can reliably identify an immune signature for AA based on Treg subpopulations. This approach also identifies an immune signature that predicts for response to IST at time of diagnosis of AA, and which may allow a more patient specific approach to future treatment decision-making in SAA. Our findings also pave the way for future novel therapeutic approaches such as expanded autologous Tregs and low dose interleukin-2 in AA.
Conflict of interest disclosure
JMI is co-founder and board member at Cytobank Inc. Tables   Table 1. Patients' characteristics: Thirty-nine AA patients were recruited in this study and PB samples were used for mass-cytometry and/or in-vitro experiments. AA patients who were eligible for IST were randomly selected and invited to participate in this study. A small to moderate PNH clone was detected in 28 patients, with no cases of hemolytic PNH. Peripheral blood mononuclear cells (PBMCs) from 16 patients (12 IST responder and 4 non-responders) were used for initial CyTOF analysis and samples from another 15 patients (11 IST responders and 4 nonresponders) were used as validation cohort. PBMCs from additional 8 patients were used for functional assays. Among non responder patients (n=14), 7 patients were transplanted later on and the remaining were treated with CsA and supportive care. following parameters which showed the highest differences between subpopulations were used for the Euclidian distance calculation: FOXP3, CD25, CD127, CD45RA, HLA-DR, CCR6, CCR4, CD69, CD27, CXCR3, CD45RO, CD4, CD20, CD95, CD161, CD28, CD152, CD7, CD279, and CD19. t-SNE1 and t-SNE2 were used for distance calculation (see also figure S10 ). 
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